SCHEMBL3445477

SCHEMBL3445477

COc1cc(-c2cc3c4cc(C)ccc4n(C)c3n(C)c2=O)cc(OC)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.40
▸ MAPT P10636 3/20 0.40
▸ HTT P42858 2/20 0.40
▸ APAF1 O14727 2/20 0.40
▸ PKM P14618 2/20 0.40
▸ IDO1 P14902 2/20 0.40
▸ MAPK1 P28482 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ MCL1 Q07820 2/20 0.40
▸ NPSR1 Q6W5P4 2/20 0.40
▸ TDP1 Q9NUW8 2/20 0.40
▸ ADORA3 P0DMS8 1/20 0.37
▸ PADI4 Q9UM07 1/20 0.36
▸ BRD9 Q9H8M2 2/20 0.36
▸ BRD7 Q9NPI1 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2385054 0.83 MAPT (0.46) KDM4EMAPTHTTAPAF1PKM
SCHEMBL2384414 0.83 PADI4 (0.44) KDM4EMAPTHTTAPAF1PKM
SCHEMBL3867984 0.82 HSD17B10 (0.46) KDM4EMAPTHTTAPAF1PKM
SCHEMBL3443882 0.80 KDM4E (0.43) KDM4EMAPTHTTAPAF1PKM
SCHEMBL2385267 0.80 KDM4E (0.43) KDM4EMAPTHTTAPAF1PKM
Hydrochloric Acid SCHEMBL3444526 0.79 KDM4E (0.42) KDM4EMAPTHTTAPAF1PKM
SCHEMBL2382248 0.78 MAPT (0.43) KDM4EMAPTHTTAPAF1PKM
SCHEMBL3445172 0.77 KDM4E (0.39) KDM4EMAPTHTTMAPK1RAB9A
SCHEMBL3443894 0.76 CYP2A6 (0.44) KDM4EMAPTHTTAPAF1PKM
SCHEMBL2384727 0.76 KDM4E (0.49) KDM4EMAPTHTTAPAF1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816368-B2 Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2010-10-19 — — US claimed
US-20090042924-A1 Pyridoindolone Derivatives Substituted in the 3-position by a Heterocyclic Group, Their Preparation and Their Application in Therapeutics SANOFI-AVENTIS (FR) 2009-02-12 — — US claimed
US-7456193-B2 Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2008-11-25 — — US claimed
EP-1556380-B1 PYRIDOINDOLONE DERIVATIVES SUBSTITUTED IN THE 3-POSITION BY A HETEROCYCLIC GROUP, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS SANOFI AVENTIS (FR) 2006-04-12 — — EP claimed
US-20050222192-A1 Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2005-10-06 — — US claimed
EP-1556380-A1 PYRIDOINDOLONE DERIVATIVES SUBSTITUTED IN THE 3-POSITION BY A HETEROCYCLIC GROUP, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS Sanofi-Aventis (FR) 2005-07-27 — — EP claimed
WO-2004037821-A1 PYRIDOINDOLONE DERIVATIVES SUBSTITUTED IN THE 3-POSITION BY A HETEROCYCLIC GROUP, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2004-05-06 — — WO claimed
US-7816368-B2 Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2010-10-19 — — US disclosed
US-20090042924-A1 Pyridoindolone Derivatives Substituted in the 3-position by a Heterocyclic Group, Their Preparation and Their Application in Therapeutics SANOFI-AVENTIS (FR) 2009-02-12 — — US disclosed
US-7456193-B2 Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2008-11-25 — — US disclosed
EP-1556380-B1 PYRIDOINDOLONE DERIVATIVES SUBSTITUTED IN THE 3-POSITION BY A HETEROCYCLIC GROUP, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS SANOFI AVENTIS (FR) 2006-04-12 — — EP disclosed
US-20050222192-A1 Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2005-10-06 — — US disclosed
EP-1556380-A1 PYRIDOINDOLONE DERIVATIVES SUBSTITUTED IN THE 3-POSITION BY A HETEROCYCLIC GROUP, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS Sanofi-Aventis (FR) 2005-07-27 — — EP disclosed
WO-2004037821-A1 PYRIDOINDOLONE DERIVATIVES SUBSTITUTED IN THE 3-POSITION BY A HETEROCYCLIC GROUP, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2004-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222192-A1 Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics CBR3, PNPO, CBR1 KDM4E 2222/4885MAPT 4161/4885HTT 2352/4885
US-20090042924-A1 Pyridoindolone Derivatives Substituted in the 3-position by a Heterocyclic Group, Their Preparation and Their Application in Therapeutics PNPO, DPYD, PDXK KDM4E 2743/4885MAPT 4064/4885HTT 4278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback